Authors' objectives: The aim of this review is to identify, assemble and summarize available evidence describing the clinical effectiveness and cost-effectiveness of dapagliflozin for the treatment of CKD.

Authors' results and conclusions: Recent, large, high-quality trials have demonstrated some benefits of dapagliflozin for the treatment of chronic kidney disease (most often in patients with type 2 diabetes) as compared to placebo. • Data describing the clinical effectiveness of dapagliflozin have identified both relative benefits and no differences compared to placebo in various measures of renal and cardiovascular health and function, as well as health care utilization, mortality, and adverse events. • A large proportion of the available data has been generated from the same randomized controlled trial that has recently been reported in multiple publications describing various patient subgroups and outcomes. • No evidence was identified describing the cost-effectiveness of dapagliflozin for the treatment of patients with chronic kidney disease.

Project Status: Completed

URL for project: https://www.cadth.ca/dapagliflozin-chronic-kidney-disease

Year Published: 2022

URL for published report: https://www.cadth.ca/sites/default/files/pdf/htis/2022/RD0065%20Dapagliflozin%20for%20CKD%20Final.pdf

English language abstract: An English language summary is available

Publication Type: Rapid Review

Country: Canada

Organisation Name: Canadian Agency for Drugs and Technologies in Health

Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;

Contact Name: requests@cadth.ca

Contact Email: requests@cadth.ca

Copyright: <p>Canadian Agency for Drugs and Technologies in Health (CADTH)</p>